Amgen Reaches U.S. Government Agreement To Lower Drug Prices, Expand Direct-To-Patient Access And Reinforce U.S. Manufacturing Investment

Underscores Long-Standing Commitment to Investing in Innovation and U.S. Manufacturing

THOUSAND OAKS, Calif., Dec. 19, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced it is taking action again with the U.S. government to lower medicine costs for American patients, while reinforcing Amgen's long-standing commitment to innovation. The action satisfies the components outlined in President Trump's July 31 letter, including the Administration's Most Favored Nation pricing requests. Additional details remain confidential.

"The U.S. leads the world in biopharmaceutical innovation, and we look forward to continued engagement with the U.S. government to see that this innovation is appropriately supported globally," said Robert A. Bradway, chairman and chief executive officer at Amgen.

Amgen will expand its direct-to-patient program, AmgenNow™, to include Aimovig® (erenumab-aooe) and Amjevita® (adalimumab-atto). Both will be available at a discounted monthly price of $299, nearly 60% and 80% lower than their current U.S. list prices, respectively. In October 2025, the company launched AmgenNow and made Repatha® (evolocumab) available to American patients at a monthly price of $239, nearly 60% below its current U.S. list price. The program is open to all eligible patients, including those who are uninsured, enrolled in high-deductible health plans or prefer to pay with cash or out of pocket. All three medicines will also be offered through TrumpRx.gov.

Since 2018, Amgen has invested more than $40 billion in manufacturing and research and development, building on its leadership in innovation and state-of-the-art operations in the U.S. These investments were facilitated by the passage of the Tax Cuts and Jobs Act (TCJA) of 2017. The enactment of pro-growth tax policies in the TCJA, reinforced by the One Big Beautiful Bill Act of 2025, further enabled Amgen to invest domestically in science and manufacturing.

This year, Amgen announced an additional $2.5 billion in U.S. manufacturing capital investments, including expansions of $900 million in Ohio and $1 billion in North Carolina. In recognition of these continued investments, Amgen will receive relief from industry-specific tariffs for the next three years.